11/15
07:20 am
spry
Loss-Making ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Expected To Breakeven In The Medium-Term [Yahoo! Finance]
Low
Report
Loss-Making ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Expected To Breakeven In The Medium-Term [Yahoo! Finance]
11/14
09:08 am
spry
NEURELIS ENTERS $208 MILLION AGREEMENT TO MONETIZE INTRAVAIL ROYALTIES [Yahoo! Finance]
Medium
Report
NEURELIS ENTERS $208 MILLION AGREEMENT TO MONETIZE INTRAVAIL ROYALTIES [Yahoo! Finance]
11/14
02:21 am
spry
ARS Pharmaceuticals Inc (SPRY) Q3 2024 Earnings Call Highlights: Strong Cash Position and NEPHI ... [Yahoo! Finance]
Medium
Report
ARS Pharmaceuticals Inc (SPRY) Q3 2024 Earnings Call Highlights: Strong Cash Position and NEPHI ... [Yahoo! Finance]
11/13
06:30 am
spry
ARS Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates
High
Report
ARS Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates
11/11
07:45 am
spry
ARS Pharmaceuticals Inks Licensing Pact For Neffy Allergic Reaction Treatment, Analyst Sees Further Stock Upside Despite 200% Surge In 2024 [Yahoo! Finance]
Low
Report
ARS Pharmaceuticals Inks Licensing Pact For Neffy Allergic Reaction Treatment, Analyst Sees Further Stock Upside Despite 200% Surge In 2024 [Yahoo! Finance]
11/11
07:00 am
spry
ARS Pharmaceuticals Announces Exclusive Agreement with Global Allergy Leader ALK to Commercialize neffy® in Europe, Canada and Other Geographies Outside the United States
Low
Report
ARS Pharmaceuticals Announces Exclusive Agreement with Global Allergy Leader ALK to Commercialize neffy® in Europe, Canada and Other Geographies Outside the United States
11/9
05:36 pm
spry
ALK licenses rights to neffy®, the first approved adrenaline nasal spray for emergency treatment of allergic reactions (anaphylaxis) [Yahoo! Finance]
Low
Report
ALK licenses rights to neffy®, the first approved adrenaline nasal spray for emergency treatment of allergic reactions (anaphylaxis) [Yahoo! Finance]
11/6
08:00 am
spry
ARS Pharmaceuticals Announces Conference Call and Webcasts for its Third Quarter 2024 Financial Results and Presentations at Upcoming Conferences
Low
Report
ARS Pharmaceuticals Announces Conference Call and Webcasts for its Third Quarter 2024 Financial Results and Presentations at Upcoming Conferences
11/4
11:00 am
spry
ARS Pharmaceuticals, Inc. Is Being Investigated For Fraud And Affected Investors Are Urged To Contact The Schall Law Firm
Low
Report
ARS Pharmaceuticals, Inc. Is Being Investigated For Fraud And Affected Investors Are Urged To Contact The Schall Law Firm
11/3
11:00 am
spry
The Schall Law Firm Encourages Shareholder Participation In An Inquiry Into ARS Pharmaceuticals Inc For Securities Law Violations
Low
Report
The Schall Law Firm Encourages Shareholder Participation In An Inquiry Into ARS Pharmaceuticals Inc For Securities Law Violations
11/2
11:00 am
spry
ARS Pharmaceuticals, Inc. Is Being Investigated For Securities Fraud And Affected Investors Are Urged To Contact The Schall Law Firm
Low
Report
ARS Pharmaceuticals, Inc. Is Being Investigated For Securities Fraud And Affected Investors Are Urged To Contact The Schall Law Firm
10/31
11:00 am
spry
The Schall Law Firm Encourages Shareholders To Join An Inquiry Into ARS Pharmaceuticals Inc For Securities Law Violations
Medium
Report
The Schall Law Firm Encourages Shareholders To Join An Inquiry Into ARS Pharmaceuticals Inc For Securities Law Violations
10/30
11:00 am
spry
ARS Pharmaceuticals, Inc. Is Being Investigated For Securities Fraud And Investors With Losses Are Urged To Contact The Schall Law Firm
Medium
Report
ARS Pharmaceuticals, Inc. Is Being Investigated For Securities Fraud And Investors With Losses Are Urged To Contact The Schall Law Firm
10/29
11:00 am
spry
The Schall Law Firm Encourages Shareholder Participation In An Inquiry Into ARS Pharmaceuticals Inc For Securities Law Violations
Low
Report
The Schall Law Firm Encourages Shareholder Participation In An Inquiry Into ARS Pharmaceuticals Inc For Securities Law Violations
10/28
11:00 am
spry
The Schall Law Firm Encourages Shareholder Participation In An Inquiry Into ARS Pharmaceuticals Inc For Securities Law Violations
Low
Report
The Schall Law Firm Encourages Shareholder Participation In An Inquiry Into ARS Pharmaceuticals Inc For Securities Law Violations
10/27
11:00 am
spry
ARS Pharmaceuticals, Inc. Is Being Investigated For Securities Fraud And Investors With Losses Are Urged To Contact The Schall Law Firm
Neutral
Report
ARS Pharmaceuticals, Inc. Is Being Investigated For Securities Fraud And Investors With Losses Are Urged To Contact The Schall Law Firm
10/26
11:00 am
spry
The Schall Law Firm Encourages Shareholders To Join An Inquiry Into ARS Pharmaceuticals Inc For Securities Law Violations
Neutral
Report
The Schall Law Firm Encourages Shareholders To Join An Inquiry Into ARS Pharmaceuticals Inc For Securities Law Violations
10/25
11:00 am
spry
ARS Pharmaceuticals, Inc. Is Being Investigated For Securities Fraud And Investors With Losses Are Urged To Contact The Schall Law Firm
Medium
Report
ARS Pharmaceuticals, Inc. Is Being Investigated For Securities Fraud And Investors With Losses Are Urged To Contact The Schall Law Firm
10/24
11:00 am
spry
The Schall Law Firm Encourages Shareholders To Join An Inquiry Into ARS Pharmaceuticals Inc For Securities Law Violations
Low
Report
The Schall Law Firm Encourages Shareholders To Join An Inquiry Into ARS Pharmaceuticals Inc For Securities Law Violations
10/24
08:30 am
spry
ARS Pharmaceuticals Showcases Intranasal Epinephrine Data at 2024 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting
Medium
Report
ARS Pharmaceuticals Showcases Intranasal Epinephrine Data at 2024 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting
10/23
11:00 am
spry
ARS Pharmaceuticals, Inc. Is Being Investigated For Securities Fraud And Affected Investors Are Urged To Reach Out To The Schall Law Firm
Low
Report
ARS Pharmaceuticals, Inc. Is Being Investigated For Securities Fraud And Affected Investors Are Urged To Reach Out To The Schall Law Firm
10/22
11:00 am
spry
The Schall Law Firm Encourages Shareholder Participation In An Inquiry Into ARS Pharmaceuticals Inc For Securities Law Violations
Low
Report
The Schall Law Firm Encourages Shareholder Participation In An Inquiry Into ARS Pharmaceuticals Inc For Securities Law Violations
10/21
11:00 am
spry
ARS Pharmaceuticals, Inc. Is Being Investigated For Securities Fraud And Investors With Losses Are Urged To Contact The Schall Law Firm
Low
Report
ARS Pharmaceuticals, Inc. Is Being Investigated For Securities Fraud And Investors With Losses Are Urged To Contact The Schall Law Firm
10/20
11:00 am
spry
The Schall Law Firm Encourages Shareholders To Join An Inquiry Into ARS Pharmaceuticals Inc For Securities Law Violations
Medium
Report
The Schall Law Firm Encourages Shareholders To Join An Inquiry Into ARS Pharmaceuticals Inc For Securities Law Violations
10/19
11:00 am
spry
ARS Pharmaceuticals, Inc. Is Being Investigated For Possible Securities Fraud And Investors With Losses Are Urged To Contact The Schall Law Firm
Medium
Report
ARS Pharmaceuticals, Inc. Is Being Investigated For Possible Securities Fraud And Investors With Losses Are Urged To Contact The Schall Law Firm